Gilead Sciences Inc has struck a $5 billion deal with Galapagos NV giving it rights to the Belgian company’s suite of small molecule drugs for inflammatory diseases as well as an equity stake in the company of up to 29.9%. The agreement also includes a pledge by Gilead to not increase its stake in Galapagos for 10 years.
